Key facts
- It has raised $93.0M; the latest was Early Stage VC in Oct 2025.
- Notable investors include CMB International Capital, Guanghua Kaiyuan Capital, B Capital China, BioTrack Capital, Fontus Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Rona Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Rona Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rona Therapeutics
Developer of an RNA therapeutics platform designed for RNA medicine discovery. The company aims to establish innovative and disruptive RNA medicines with a proprietary platform to enable therapeutics with more specific, stable and prolonged effects. The company is building state-of-the-art facilities to expand nucleic acid synthesis, delivery platform, oligonucleotide chemical modification, RNA biology and manufacturing capability to realize the potential of powerful RNA therapeutics.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- ronatherapeutics.com/
- Ownership
- Privately Held (backing)
Rona Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rona Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rona Therapeutics in its N-PORT filings yet. We sweep new filings monthly.